Table of Contents
ISRN Medicinal Chemistry
Volume 2014 (2014), Article ID 203518, 14 pages
http://dx.doi.org/10.1155/2014/203518
Research Article

1,4-Dihydropyridine Calcium Channel Blockers: Homology Modeling of the Receptor and Assessment of Structure Activity Relationship

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt

Received 28 September 2013; Accepted 5 December 2013; Published 10 February 2014

Academic Editors: R. B. de Alencastro, P. L. Kotian, O. A. Santos-Filho, L. Soulère, and S. Srichairatanakool

Copyright © 2014 Moataz A. Shaldam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Miller, “Multiple calcium channels and neuronal function,” Science, vol. 235, no. 4784, pp. 46–52, 1987. View at Google Scholar · View at Scopus
  2. G. J. Augustine, M. P. Charlton, and S. J. Smith, “Calcium action in synaptic transmitter release,” Annual Review of Neuroscience, vol. 10, pp. 633–693, 1987. View at Google Scholar · View at Scopus
  3. V. Leuranguer, M. E. Mangoni, J. Nargeot, and S. Richard, “Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects,” Journal of Cardiovascular Pharmacology, vol. 37, no. 6, pp. 649–661, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Schultz, G. Mikala, A. Yatani et al., “Cloning, chromosomal localization, and functional expression of the α1 subunit of the L-type voltage-dependent calcium channel from normal human heart,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 6228–6232, 1993. View at Google Scholar · View at Scopus
  5. R. D. Zühlke, A. Bouron, N. M. Soldatov, and H. Reuter, “Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human α(1C) subunit gene,” FEBS Letters, vol. 427, no. 2, pp. 220–224, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. N. M. Soldatov, A. Bouron, and H. Reuter, “Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants,” Journal of Biological Chemistry, vol. 270, no. 18, pp. 10540–10543, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. N. M. Soldatov, R. D. Zühlke, A. Bouron, and H. Reuter, “Molecular structures involved in L-type calcium channel inactivation. Role of the carboxyl-terminal region encoded by exons 40-42 in α(1C) subunit in the kinetics and Ca2+ dependence of inactivation,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3560–3566, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Swarnalatha, G. Prasanthi, N. Sirisha, and C. Madhusudhana Chetty, “1,4-Dihydropyridines: a multtifunctional molecule: a review,” International Journal of ChemTech Research, vol. 3, no. 1, pp. 75–89, 2011. View at Google Scholar · View at Scopus
  9. A. Fleckenstein, “Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle,” Annual Review of Pharmacology and Toxicology, vol. 17, pp. 149–166, 1977. View at Google Scholar · View at Scopus
  10. D. J. Triggle, “Calcium channel antagonists: clinical uses-Past, present and future,” Biochemical Pharmacology, vol. 74, no. 1, pp. 1–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Loev, M. M. Goodman, K. M. Snader, R. Tedeschi, and E. Macko, “‘Hantzsch-type’ dihydropyridine hypotensive agents,” Journal of Medicinal Chemistry, vol. 17, no. 9, pp. 956–965, 1974. View at Google Scholar · View at Scopus
  12. J. G. Breitenbucher and G. Figliozzi, “Solid-phase synthesis of 4-aryl-1,4-dihydropyridines via the Hantzsch three component condensation,” Tetrahedron Letters, vol. 41, no. 22, pp. 4311–4315, 2000. View at Google Scholar · View at Scopus
  13. R. Boer and V. Gekeler, “Chemosensitizers in tumor therapy: new compounds promise better efficacy,” Drugs of the Future, vol. 20, no. 5, pp. 499–509, 1995. View at Google Scholar · View at Scopus
  14. V. M. Bryukhanov, F. Zverev Ya., and V. I. Elkin, “Effects of calcium antagonists on the development of inflammatory edema in rats,” Experimental and Clinical Pharmacology, vol. 57, no. 2, pp. 47–49, 1994. View at Google Scholar · View at Scopus
  15. S. Bahekar and D. Shinde, “Synthesis and anti-inflammatory activity of 1-4-dihydropyridines,” Acta Pharmaceutica, vol. 52, no. 4, pp. 281–287, 2002. View at Google Scholar · View at Scopus
  16. G. A. Wächter, M. C. Davis, A. R. Martin, and S. G. Franzblau, “Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids,” Journal of Medicinal Chemistry, vol. 41, no. 13, pp. 2436–2438, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gullapalli and P. Ramarao, “L-type Ca2+ channel modulation by dihydropyridines potentiates κ-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats,” Neuropharmacology, vol. 42, no. 4, pp. 467–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. C. E. Sunkel, M. Fau de Casa-Juana, L. Santos et al., “4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists,” Journal of Medicinal Chemistry, vol. 33, no. 12, pp. 3205–3210, 1990. View at Google Scholar · View at Scopus
  19. K. Cooper, M. J. Fray, M. J. Parry, K. Richardson, and J. Steele, “1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives,” Journal of Medicinal Chemistry, vol. 35, no. 17, pp. 3115–3129, 1992. View at Google Scholar · View at Scopus
  20. D. J. Triggle, “The pharmacology of ion channels: with particular reference to voltage-gated Ca2+ channels,” European Journal of Pharmacology, vol. 375, no. 1–3, pp. 311–325, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Hemmateenejad, R. Miri, M. Akhond, and M. Shamsipur, “QSAR study of the calcium channel antagonist activity of some recently synthesized dihydropyridine derivatives. An application of genetic algorithm for variable selection in MLR and PLS methods,” Chemometrics and Intelligent Laboratory Systems, vol. 64, no. 1, pp. 91–99, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Hemmateenejad, R. Miri, M. Akhond, and M. Shamsipur, “Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method,” Archiv der Pharmazie, vol. 335, no. 10, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Hemmateenejad, M. Akhond, R. Miri, and M. Shamsipur, “Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous),” Journal of Chemical Information and Computer Sciences, vol. 43, no. 4, pp. 1328–1334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Hemmateenejad, M. A. Safarpour, R. Miri, and F. Taghavi, “Application of ab initio theory to QSAR study of 1,4-dihydropyridine-based calcium channel blockers using GA-MLR and PC-GA-ANN procedures,” Journal of Computational Chemistry, vol. 25, no. 12, pp. 1495–1503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Hemmateenejad, R. Miri, M. A. Safarpour, M. Khoshneviszadeh, and N. Edraki, “Conformational analysis of some new derivatives of 4-nitroimidazolyl-1,4- dihydropyridine-based calcium channel blockers,” Journal of Molecular Structure, vol. 717, no. 1–3, pp. 139–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Miri, K. Javidnia, A. Kebriaie-Zadeh et al., “Synthesis and evaluation of pharmacological activities of 3,5-dialkyl 1,4-dihydro-2,6-dimethyl-4-nitroimidazole-3,5-pyridine dicarboxylates,” Archiv der Pharmazie, vol. 336, no. 9, pp. 422–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Navidpour, H. Shafaroodi, R. Miri, A. R. Dehpour, and A. Shafiee, “Lipophilic 4-imidazoly-1,4-dihydropyridines: synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure,” Farmaco, vol. 59, no. 4, pp. 261–269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Safarpour, B. Hemmateenejad, R. Miri, and M. Jamali, “Quantum chemical-QSAR study of some newly synthesized 1,4-Dihydropyridine calcium channel blockers,” QSAR and Combinatorial Science, vol. 22, no. 9-10, pp. 997–1005, 2004. View at Google Scholar · View at Scopus
  29. D. J. Triggle, “1,4-Dihydropyridines as calcium channel ligands and privileged structures,” Cellular and Molecular Neurobiology, vol. 23, no. 3, pp. 293–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. U. Bowie, R. Lüthy, and D. Eisenberg, “A method to identify protein sequences that fold into a known three-dimensional structure,” Science, vol. 253, no. 5016, pp. 164–170, 1991. View at Google Scholar · View at Scopus
  31. E. Perez-Reyes, X. Wei, A. Castellano, and L. Birnbaumer, “Molecular diversity of L-type calcium channels. Evidence for alternative splicing of the transcripts of three non-allelic genes,” Journal of Biological Chemistry, vol. 265, no. 33, pp. 20430–20436, 1990. View at Google Scholar · View at Scopus
  32. UniProtKB/Swiss-Prot, 2013, http://www.uniprot.org/uniprot/Q13936.
  33. L. Yu, C. Sun, D. Song et al., “Nuclear magnetic resonance structural studies of a potassium channel-charybdotoxin complex,” Biochemistry, vol. 44, no. 48, pp. 15834–15841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. B. S. Zhorov, E. V. Folkman, and V. S. Ananthanarayanan, “Homology model of dihydropyridine receptor: implications for L-type Ca2+ channel modulation by agonists and antagonists,” Archives of Biochemistry and Biophysics, vol. 393, no. 1, pp. 22–41, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Sali, L. Potterton, F. Yuan, H. Van Vlijmen, and M. Karplus, “Evaluation of comparative protein modeling by MODELLER,” Proteins, vol. 23, no. 3, pp. 318–326, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. M.-Y. Shen and A. Sali, “Statistical potential for assessment and prediction of protein structures,” Protein Science, vol. 15, no. 11, pp. 2507–2524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Z. Spassov, L. Yan, and P. K. Flook, “The dominant role of side-chain backbone interactions in structural realization of amino acid code. ChiRotor: a side-chain prediction algorithm based on side-chain backbone interactions,” Protein Science, vol. 16, no. 3, pp. 494–506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Z. Spassov, P. K. Flook, and L. Yan, “LOOPER: a molecular mechanics-based algorithm for protein loop prediction,” Protein Engineering, Design and Selection, vol. 21, no. 2, pp. 91–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Z. Spassov and Y. A. N. Lisa, “A fast and accurate computational approach to protein ionization,” Protein Science, vol. 17, no. 11, pp. 1955–1970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Jiang, A. Lee, J. Chen et al., “X-ray structure of a voltage-dependent K+ channel,” Nature, vol. 423, no. 6935, pp. 33–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. S. B. Long, E. B. Campbell, and R. MacKinnon, “Crystal structure of a mammalian voltage-dependent Shaker family K+ channel,” Science, vol. 309, no. 5736, pp. 897–903, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. G. M. Lipkind and H. A. Fozzard, “KcsA crystal structure as framework for a molecular model of the Na+ channel pore,” Biochemistry, vol. 39, no. 28, pp. 8161–8170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Huber, E. Wappl, A. Herzog et al., “Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain,” Biochemical Journal, vol. 347, no. 3, pp. 829–836, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Corpet, “Multiple sequence alignment with hierarchical clustering,” Nucleic Acids Research, vol. 16, no. 22, pp. 10881–10890, 1988. View at Publisher · View at Google Scholar · View at Scopus
  45. S. C. Lovell, I. W. Davis, W. B. Arendall III et al., “Structure validation by Cα geometry: φ,ψ and Cβ deviation,” Proteins, vol. 50, no. 3, pp. 437–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Colovos and T. O. Yeates, “Verification of protein structures: patterns of nonbonded atomic interactions,” Protein Science, vol. 2, no. 9, pp. 1511–1519, 1993. View at Google Scholar · View at Scopus
  47. V. B. Chen, W. B. Arendall III, J. J. Headd et al., “MolProbity: all-atom structure validation for macromolecular crystallography,” Acta Crystallographica D, vol. 66, no. 1, pp. 12–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. I. W. Davis, L. W. Murray, J. S. Richardson, and D. C. Richardson, “MolProbity: structure validation and all-atom contact analysis for nucleic acids and their complexes,” Nucleic Acids Research, vol. 32, pp. W615–W619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. I. W. Davis, A. Leaver-Fay, V. B. Chen et al., “MolProbity: all-atom contacts and structure validation for proteins and nucleic acids,” Nucleic Acids Research, vol. 35, pp. W375–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. J. Sippl, “Recognition of errors in three-dimensional structures of proteins,” Proteins, vol. 17, no. 4, pp. 355–362, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Wiederstein and M. J. Sippl, “ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins,” Nucleic Acids Research, vol. 35, pp. W407–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Lüthy, J. U. Bowie, and D. Eisenberg, “Assesment of protein models with three-dimensional profiles,” Nature, vol. 356, no. 6364, pp. 83–85, 1992. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Bhattacharya, Z. Wunderlich, D. Monleon, R. Tejero, and G. T. Montelione, “Assessing model accuracy using the homology modeling automatically (HOMA) software,” Proteins, vol. 70, no. 1, pp. 105–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Llorca, M. Betti, J. M. González, A. Valencia, A. J. Márquez, and J. M. Valpuesta, “The three-dimensional structure of an eukaryotic glutamine synthetase: functional implications of its oligomeric structure,” Journal of Structural Biology, vol. 156, no. 3, pp. 469–479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Teilum, J. C. Hoch, V. Goffin, S. Kinet, J. A. Martial, and B. B. Kragelund, “Solution structure of human prolactin,” Journal of Molecular Biology, vol. 351, no. 4, pp. 810–823, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Ginalski, “Comparative modeling for protein structure prediction,” Current Opinion in Structural Biology, vol. 16, no. 2, pp. 172–177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Petrey and B. Honig, “Protein structure prediction: inroads to biology,” Molecular Cell, vol. 20, no. 6, pp. 811–819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. K. Beissenhirtz, F. W. Scheller, M. S. Viezzoli, and F. Lisdat, “Engineered superoxide dismutase monomers for superoxide biosensor applications,” Analytical Chemistry, vol. 78, no. 3, pp. 928–935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Mansfeld, S. Gebauer, K. Dathe, and R. Ulbrich-Hofmann, “Secretory phospholipase A2 from Arabidopsis thaliana: insights into the three-dimensional structure and the amino acids involved in catalysis,” Biochemistry, vol. 45, no. 18, pp. 5687–5694, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. R. A. Engh and R. Huber, “Structure quality and target parameters,” in International Tables for Crystallography Volume F: Crystallography of Biological Macromolecules, M. G. Rossmann and E. Arnold, Eds., pp. 382–392, Kluwer Academic Publishers, Dordrecht, The Netherlands, 2001. View at Google Scholar
  61. B. Z. Peterson and W. A. Catterall, “Calcium binding in the pore of L-type calcium channels modulates high affinity dihydropyridine binding,” Journal of Biological Chemistry, vol. 270, no. 31, pp. 18201–18204, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Pedemonte, D. Boido, O. Moran et al., “Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel,” Molecular Pharmacology, vol. 72, no. 1, pp. 197–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. C. O. Kappe, “4-Aryldihydropyrimidines via the Biginelli condensation: aza-analogs of nifedipine-type calcium channel modulators,” Molecules, vol. 3, no. 1, pp. 1–9, 1998. View at Google Scholar · View at Scopus
  64. H. Ito, N. Klugbauer, and F. Hofmann, “Transfer of the high affinity dihydropyridine sensitivity from L-type to non-L-type calcium channel,” Molecular Pharmacology, vol. 52, no. 4, pp. 735–740, 1997. View at Google Scholar · View at Scopus
  65. T. F. El-Moselhy, “QSAR and docking studies of 1, 4-dihydropyridine calcium antagonists with methylsulfonylimidazolyl substituent based on genetic function approximation,” Chemistry and Biology Interface, vol. 2, pp. 172–182, 2012. View at Google Scholar
  66. R. Miri, K. Javidnia, H. Sarkarzadeh, and B. Hemmateenejad, “Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist,” Bioorganic and Medicinal Chemistry, vol. 14, no. 14, pp. 4842–4849, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. W. G. Nayler, “Amlodipine an overview,” Clinical Drug Investigation, vol. 13, no. 1, pp. 1–11, 1997. View at Google Scholar · View at Scopus
  68. T. F. El-Moselhy, “Lipophilic 4-imidazolyl-1, 4-dihydropyridines: synthesis, calcium channel antagonist activity and docking study,” Chemistry and Biology Interface, vol. 3, pp. 123–136, 2013. View at Google Scholar
  69. A. Foroumadi, N. Analuie, M. Rezvanipour et al., “Synthesis and calcium channel antagonist activity of nifedipine analogues with methylthioimidazole substituent,” Farmaco, vol. 57, no. 3, pp. 195–199, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Hosseini, R. Miri, M. Amini et al., “Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methy 1-4,5-dichloroimidazolyl substituents,” Archiv der Pharmazie, vol. 340, no. 10, pp. 549–556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Shafiee, A. R. Dehpour, F. Hadizadeh, and M. Azimi, “Syntheses and calcium channel antagonist activity of nifedipine analogue with methylsulfonylimidazolyl substituent,” Pharmaceutica Acta Helvetiae, vol. 73, no. 2, pp. 75–79, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Zarghi, H. Sadeghi, A. Fassihi, M. Faizi, and A. Shafiee, “Synthesis and calcium antagonist activity of 1,4-dihydropyridines containing phenylaminoimidazolyl substituents,” Farmaco, vol. 58, no. 11, pp. 1077–1081, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Senatore, A. N. Boone, S. Lam, T. F. Dawson, B. S. Zhorov, and J. D. Spafford, “Mapping of dihydropyridine binding residues in a less sensitive invertebrate L-type calcium channel (LCav1),” Channels, vol. 5, no. 2, pp. 173–187, 2011. View at Google Scholar · View at Scopus
  74. J. Tamargo, J. López-Sendón, E. Delpon, M. González-Morales, and E. de Miguel, “Cardiovascular effects of the new dihydropyridine derivative elgodipine,” Arzneimittel-Forschung, vol. 41, no. 9, pp. 895–900, 1991. View at Google Scholar · View at Scopus
  75. N. Daryabari, T. Akbarzadeh, M. Amini, R. Miri, H. Mirkhani, and A. Shafiee, “Synthesis and calcium channel antagonist activities of new derivatives of dialkyl 1,4-dihydro-2,6-dimethyl-4-(5-phenylisoxazol-3-yl)pyridine-3,5-dicarboxylates,” Journal of the Iranian Chemical Society, vol. 4, no. 1, pp. 30–36, 2007. View at Google Scholar · View at Scopus
  76. A. Shafiee, A.-R. Dehpour, F. Hadizadeh, and B. Rezaei, “Synthesis and calcium channel antagonist activity of nifedipine analogues with chloroindolyl substituent,” DARU Journal of Pharmaceutical Sciences, vol. 8, no. 3-4, pp. 32–36, 2000. View at Google Scholar · View at Scopus
  77. T. F. El-Moselhy, “Synthesis of 1, 4-Dihydropyridine Hantzsch Ester as potential calcium channel blockers,” Alexandria Journal of Pharmaceutical Sciences, vol. 16, pp. 35–39, 2002. View at Google Scholar
  78. K. Kuroda, Y. Fukuda, K. Nakao, and T. Inukai, “Effects of felodipine on vascular smooth muscle in comparison with nifedipine,” Arzneimittel-Forschung, vol. 41, no. 7, pp. 709–714, 1991. View at Google Scholar · View at Scopus
  79. D. Hadjipavlou-Litina, “Calcium ion channels and their blockers,” in Ion Channels and Their Inhibitors, S. P. Gupta, Ed., pp. 265–288, Springer, New York, NY, USA, 2011. View at Google Scholar